ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 93 filers reported holding ACCELERON PHARMA INC in Q2 2014. The put-call ratio across all filers is 0.08 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $683,740,000 | +23.7% | 3,972,924 | -9.8% | 0.02% | +26.7% |
| Q2 2021 | $552,563,000 | -12.0% | 4,403,225 | -4.9% | 0.02% | -16.7% |
| Q1 2021 | $627,737,000 | +6.4% | 4,628,978 | +0.4% | 0.02% | -5.3% |
| Q4 2020 | $590,035,000 | +13.0% | 4,611,814 | -0.6% | 0.02% | 0.0% |
| Q3 2020 | $522,254,000 | +23.6% | 4,641,005 | +4.6% | 0.02% | +11.8% |
| Q2 2020 | $422,656,000 | -8.1% | 4,436,412 | -13.3% | 0.02% | -26.1% |
| Q1 2020 | $460,072,000 | +77.5% | 5,119,301 | +4.7% | 0.02% | +130.0% |
| Q4 2019 | $259,153,000 | +26.7% | 4,887,801 | -5.6% | 0.01% | +11.1% |
| Q3 2019 | $204,488,000 | +1.1% | 5,175,558 | +5.2% | 0.01% | 0.0% |
| Q2 2019 | $202,191,000 | -9.5% | 4,921,880 | +2.6% | 0.01% | -10.0% |
| Q1 2019 | $223,420,000 | +15.8% | 4,797,511 | +8.3% | 0.01% | 0.0% |
| Q4 2018 | $192,880,000 | -22.5% | 4,428,894 | +1.9% | 0.01% | -9.1% |
| Q3 2018 | $248,830,000 | +22.0% | 4,347,892 | +3.4% | 0.01% | +22.2% |
| Q2 2018 | $204,030,000 | +29.5% | 4,205,069 | +4.3% | 0.01% | +12.5% |
| Q1 2018 | $157,575,000 | -21.5% | 4,030,059 | -14.8% | 0.01% | -20.0% |
| Q4 2017 | $200,832,000 | +25.2% | 4,732,135 | +10.1% | 0.01% | +25.0% |
| Q3 2017 | $160,399,000 | +31.8% | 4,298,012 | +7.3% | 0.01% | +33.3% |
| Q2 2017 | $121,719,000 | +25.1% | 4,005,228 | +9.0% | 0.01% | +20.0% |
| Q1 2017 | $97,266,000 | +4731.9% | 3,674,593 | +4559.6% | 0.01% | +66.7% |
| Q4 2016 | $2,013,000 | +58.8% | 78,860 | +125.1% | 0.00% | +50.0% |
| Q3 2016 | $1,268,000 | +4.9% | 35,040 | -1.5% | 0.00% | 0.0% |
| Q2 2016 | $1,209,000 | +36.0% | 35,581 | +5.6% | 0.00% | +100.0% |
| Q1 2016 | $889,000 | -36.7% | 33,682 | +17.0% | 0.00% | -50.0% |
| Q4 2015 | $1,404,000 | +68.3% | 28,795 | -14.0% | 0.00% | +100.0% |
| Q3 2015 | $834,000 | -20.3% | 33,495 | +1.2% | 0.00% | -50.0% |
| Q2 2015 | $1,047,000 | -18.8% | 33,095 | -2.3% | 0.00% | 0.0% |
| Q1 2015 | $1,290,000 | +2.5% | 33,883 | +5.0% | 0.00% | 0.0% |
| Q4 2014 | $1,258,000 | +10383.3% | 32,283 | +8329.0% | 0.00% | – |
| Q3 2014 | $12,000 | -7.7% | 383 | 0.0% | 0.00% | – |
| Q2 2014 | $13,000 | +85.7% | 383 | +90.5% | 0.00% | – |
| Q1 2014 | $7,000 | – | 201 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |